PHARMA PRICING & MARKET ACCESS INNOVATION SUMMIT
We are pleased to invite you to the Pharma Pricing & Market Access Innovation Summit on September 27th – 28th, 2018.
This Summit will bring together industry leaders and experts to discuss the latest findings, best practices, and newest technologies regarding Pharma Pricing & Market Access. Industry professionals will be seeking answers to some of the field’s biggest challenges including: increasing access to the market, pursuing innovation, and learning how to take smart risks when engaging with the market. Attendees will have the opportunity to learn from these experts and network with them to make practical solutions and develop Pharma Pricing & Market Access.
It is an honour to host this summit, and it’s a privilege to invite you to partake. We look forward to your participation in September!
Key Practical Learning Points of the Summit:
– Healthcare payer budget constraints: Any win-win solutions?
– New Realities in Pharma Industry: Rethinking the Value Chain
– Value Frameworks Proposed in the United States: Overview and Discussion of Use
– Managed Entry Agreements (MEAs) – design principles and attention points
– Data Requirements of IQWiG and G-BA
– The UK changing landscape for access to medicines
– Multi-stakeholder approach, Experience & Segmentation Analytics to ensure Access
– How to manage patient access in rare disease with evidence driven approach
– Rare Diseases and Orphan Drugs: A Market Access Outlook
– Update on pharmaceutical pricing in Japan
Who Should Attend:
CEOs / Presidents / MDs, CCOs/CMOs/CDOs, Chief Executives, Directors, Vice Presidents, Department Heads, Leaders and Managers specialising in:
Health Technology Assessment
Real World Evidence
– International and regional health authorities and regulators
– Pharmaceutical, Vaccines, & Biotechnology companies
– Clinical Research Organization (CRO) service providers
– Business Process Outsourcing (BPO) service providers
– Technology Vendors/Portal Service Providers
For any enquiry on regards to special offers & group discounts please contact us directly at:
Lidia is qualified in Medicine with a postgraduate education in Psychiatry, which she obtained from EMBA in Antwerp Management School. Lidia has almost 20 years in the pharmaceutical industry with regional and country operational management experience. A consistent record of business turnarounds, delivering substantial growth, top ranking market share positions and strong financial results as measured by multi-million-dollar P&Ls under responsibility. Successful results were recognized through promotions from sales rep, progressively increasing marketing and sales roles to Franchise Head. For the last 2 years, Lidia has been working in Health & Value, being responsible for innovative contracting, insight strategy, health economics modelling, partnership management, payer excellence, and patient access programs. Her success is driven by a strategic view, with a sharp focus on what matters and the ability to identify customer/stakeholder needs.
Patti Jewell, MPA, is Senior Director, US Government Relations & Public Affairs for Oncology in Pfizer’s Corporate Affairs Division. In this role, Patti leads Pfizer’s strategies related to federal and state cancer policy issues and public affairs engagements. She also leads the company’s work with cancer patient advocacy organizations in the policy arena. Prior to this role, Patti worked in Alliance Develop- ment, State Government Relations and Grassroots Advocacy for Pfizer. Patti was a Legislative Assistant to US Senator Mitch McConnell before joining Pfizer. She received her Masters in Public Administration from New York University and undergraduate degree in Political Science from the University of Michigan.
Graduated from Anadolu University Faculty of Medicine. Çetin got his masters degree from Hacettepe University on Health- care Management. Attended various certificate programs on Health Economics and Pharmacoeconomics in Harvard Univer- sity, London School of Economics, Vienna School of Clinical Research and International Society for Pharmacoeconomics and Outcomes Research. He has worked as Deputy Coordina- tor responsible for Health Economics Department at the Minis- try of Health – Health Project Coordination Unit (World Bank Health Project). Currently working as Market Access Coordina- tor in Association of Research-Based Pharmaceutical Compa- nies (AIFD). Prior to his job at AİFD Çetin was working as Market Access Director in BayerTurk Pharmaceuticals, Market Access Manager in Sanofi Group Turkey and as a Health Policy Associ- ate Coordinator in Pfizer Turkey. Experienced in pharmaceuti- cal sector key policy issues such as; market access, reimburse- ment, pricing, health economics/pharmacoecomics, health policy, IPR, market analytics and public affairs.
Michele Siccardi is the Head of Program Realization, Patient Value and Access for Takeda Pharmaceutical International in Zurich. In his current role he drives Market Access above-brand strategic initiatives and programs that enable Takeda transformation towards a customer centric specialty care provider. Before joining Takeda, Michele spent more than 13 years in the Industry developing significant experience in Strategic Planning, Commercial Excellence and Business Operations for both large (J&J and Medtronic) and mid-size players (Mallinckrodt Pharmaceutical and Covidien). Michele holds a full time MBA with specialization in Strategy and Finance from Schulich School of Business (York University, Toronto) and a Master of Science in Economics from LUISS University in Rome.
After studying statistics at the University of Dortmund (Germany) in 1988, Friedhelm Leverkus worked at the Social Research Centre in Dortmund. In 1991 he started his career at Pfizer Pharma GmbH as a biometrician. In this capacity he planned and analyzed clinical studies. In 1995 he was named Head of Biometrics. He was in charge of biometric support for clinical trials and NIS studies. He leads the Health Technology Assessment Group at Pfizer Germany, which is responsible for HTA and outcomes research, since 2010. The group is mainly responsible for development of AMNOG-Dossiers. For years he’s in an active cooperation with a subcommittee for vfa (Die forschenden Pharma-Unternehmen, Germany).
Weiwei works in Teva’s European headquarter as Director Market Access & Pricing, in the area of pain and headache. She is responsible for market access and pricing strategy in the European markets. Before joining Teva, she worked as a senior consultant in the strategic market access team in Pharmerit. Prior to that she worked in Nanjing Medical University as a lecturer and practiced as a physician in Internal medicine in China. Weiwei is qualified in Medicine in Nanjing Medical University, China. She also holds PhD in Health economic & Policy in Erasmus University of Rotterdam, the Netherlands.
Dr. Flammer has responsibility for Global Market Access, Epidemiology & Real World Evidence, Data Science and Patient Advocacy Relations. Martina operates at the forefront of functional developments in Market Access, Pricing & HEOR, Epidemiology and Real World Evidence (RWE) to advance state-of-the-art standards and ensure they are consistently applied and met throughout the organization from drug development, via product launches to lifecycle management. Together with her leadership team, Martina integrates novel data-scientific methods to drive efficiencies in medical and commercial data generation, data synthesis and data utiliza- tion across BI that provides medical and/or commercial value to customers. In-depth functional and customer knowledge informs functional market shaping. It also enables to champi- on new business models and value-adding collaborative partnership concepts with payers, organized providers and patient advocacy groups, across and beyond selling product. Prior to joining BI, Dr. Flammer worked at Pfizer’s New York headquarters for 11 years where she held various leadership roles in global medical and commercial settings. Martina launched 3 medicines in Pfizer’s key drug franchises and after completing her MBA, she transitioned to a commercial role in market access and evaluation of business models in emerging markets. She received 3 distinguished leadership awards, a Pharmaceutical Executive Best Brand Award and with her team a Prix Gallien for best new molecule.
Mata Charokopou joined UCB in 2015, she is currently the Health Economics Lead, Global Patient Access & Value. She is responsible for leading the Health Economics, Global Market Access & Pricing team. She is also working for UCB portfolio (immunology, neurology and bone) for Health Technology Assessment and Health Economics strategy. In her position she holds the responsibility for the design, development and implementation global health economics, pricing and value proposition strategies and projects to generate compelling evidence that demonstrates the clinical, humanistic and economic value of UCB’s compound/patient solution in the development and/or in-market portfolio to payers and aligned healthcare decision makers in the following therapeutic areas: Immunology, Bone and Central Nervous System (CNS). Prior to UCB, Mata was a Research Consultant at Pharmerit International, from 2010 till 2015, a consultancy firm specializing in Health Economics & Outcomes Research and Strategic Market Access where she took her first career steps. Mata holds a MSc in Health Economics , Policy & Law in Erasmus University of Rotterdam (Netherlands).
Ricardo has several years of experience on the Pharmaceutical Industry. He started his career as Sales & Marketing Account at Bristol-Myers Squibb from 2001 till 2008. After, Ricardo undertook several other roles such as Associate Marketing Director Europe, Specialty Care Director and MCM Marketing Director Spain & Portugal. He joined Gilead in 2015 and he is currently the Business Unit Director. Ricardo was also a Post-Graduation Professor and Principal Lecturer on Health Management Programs at CESPU.
Santoke works in IQvIA’s UK & Republic of Ireland Market Access team as Principal. He is responsible for the strategy and direction for Market Access across IQVIA. He has worked within pharma and biotech for 17 years, with experience in the UK and EU. Previously Santoke held the position of Managing Director at Pierre Fabre Ltd and worked in Marketing, Market Access, medical and sales at BMS, Novartis, Wyeth and Cambridge Labs. His areas of expertise are the UK landscape and market access, pharmaceutical structures an resource management within various leadership roles and strategy and portfolio management of pre and post launch. Santoke holds a BSc in Biochemistry/Chemistry from the University of Leeds.
Peter Rutherford is Global Medical Lead for Vifor Pharma and is involved in bringing new products for patients with rare renal diseases. After qualifying in Medicine in the UK he embarked on an academic nephrology training in the UK and USA before becoming a UK NHS Consultant nephrologist, hospital medical director and clinical advisor to NICE. He moved to industry in 2007 as Regional Medical Director in Baxter healthcare and then led the Integrated Market Access group at Quintiles from 2015 until 2017. In this present role since September 2017 is involved in market entry of 2 products for patients with significant unmet medical need.
Patrick Mollon, MD, ESSEC MBA, MSc acquired his medical qualification in the Lyon School of Medicine, France where he also gained a Master’s Degree in Medical and Biological Sciences, including Pharmacology, Psychology, and Medical Statistics. Prior to this, he received an MBA from the Superior School of Business and Administration and Economics (ESSEC) in Paris. He then worked as a Clinician, practicing General Medicine as well as being a Registrar in Emergency Medicine and Intensive Care in a University Teaching Hospital in Lyon, France. He started his Pharmaceutical Career in Pfizer Central Research as a Clinical Research Physician and then joined the Outcomes Research Division where he held a number of successive positions in the Product Development Group and the Medical division. Patrick has extensive experience in developing and implementing Health Economic strategies to support developmental compounds in a number of therapeutic areas, including Cardiovascular, Urology, Anti-Virals, Dermato-Immunology, and Rare Disesases, leading the value identification and demonstration efforts for Market Access and Health Technology Assessment from a Global perspective. As such, he is leading the development of Patient Reported Outcomes tools, Health-Economic and Budget-Impact models, Value Dossiers and Real World Evidence. Patrick has a number of publications in the area of Health-Economics and Outcomes Research. His main interests are in health-economic modelling methods and applications as well as patient-reported outcomes and decision-making.
Dražen is qualified in Medicine with a postgraduate education in bioscience and a MBA degree. He has 15 years of experience in pharmaceutical industry in almost all fields. Most of Dražen’s professional experience was in the field of oncology, which gave him a valuable experience of overcoming hurdles in access to innovation in demanding environment. He is currently Market Access Director responsible for leading Market Access team and establishing access cross-functional collaboration in Roche Croatia.
Currently, Mr.Sehram Zayer is the Managing Director of Merck Turkey. He had worked as a director and then as a CFO between 1998-2003 and 2003-2006 in the finance departments of Johnson & Johnson Turkey, Middle East and Siemens Health Care (Dade Behring) respectively. Mr. Zayer is graduated from Bosphorus University, Faculty of Business Administration and he also has CMA and CFM (Finance and Management Account- ing) certificates from Institute of Management Accountant located in USA. Besides, he is a board member of Institute Management Accountant’s İstanbul Branch and Association of Research-Based Pharmaceutical Companies (AIFD) in Turkey. In addition to his role at the Association, he is the member of Audit Commission of AIFD. Prior to his current position, he was CFO of Merck Turkey between the years of 2006-2014.
Jörg Mahlich is a health economist for Janssen, Pharmaceutical Companies of Johnson and Johnson. Prior to his current position, he was an economist for the Austrian Economic Chamber. He has also been a lecturer at the University of Vienna and Fachhochschule Wien. He received his diploma in economics from Christian-Albrechts-Universitat zu Kiel and a Ph.D in economics in 2000 at the University of Vienna.